Medical network - on April 11, in the early 1940 s, penicillin (penicillin) officially listed, created the glorious era of antibiotics. Since then, more than 70 years with beta lactam antibiotics (penicillin, cephalosporin and carbon alkene, etc.) as the "leader" of all kinds of antibiotic products appeared, development become more than a dozen major categories and hundreds of varieties of large family, the effective control of harmful human infectious diseases. 

 

But come back soon. Since the 1990 s, the bacteria (microbial) methicillin-resistant quietly appear, coupled with community-acquired pneumonia refractory disease spread quickly in Europe and the United States, such as clinical medicine. 

 

How to curb the development of increasingly rampant drug resistant strains of disease? International antibiotics industry face unprecedented significant challenges. At the time, don't say the new beta lactam antibiotics, even by the international medical community as "against drug-resistant strains of the last line of defense" of vancomycin to methyl and vancomycin are powerless in front of the bacteria. 

 

Clinical manifestations of good 

 

As people are helpless when, in 2004, by the American lilly pharmaceutical company new product development and production of a new mechanism of antibiotics of fosomycin (daptomycin) listed in the us. 

 

Previous including carbon penicillium alkene (that is, the various "culture south class" drugs) and pbo alkane ketone products (rina thiazole alkanes) products such as the new antibiotics, but found that in the process of clinical use of drugs to the antibiotics against resistant strains disease of the actual effect is not ideal, so da when genetically altered just listed has caused great sensation is not in the world. People think that it is also a kind of new common antibiotic products. 

 

But for supporting the clinical manifestation is refreshing and its antibiotic with previously listed the role of the old masters. According to introducing, in the main role of toxin is, the interference on a widely exist in the bacterial cell walls of special enzyme peptide enzymatic biosynthesis, make pathogens cannot successful synthesis of cell wall, eventually die. This unique mechanism of action is difficult to produce different kinds of pathogenic microorganism resistance. 

 

Although to never do advertising, but the effect of the most telling. Up to Joe just 2 years after the market, quickly occupied the United States more than 2000 hospitals and pharmacies, emergency center become the most trusted doctors in the United States against drug-resistant strains of the disease. Use of after drug, the patient can heal quickly, and greatly shorten the length of hospital stay, although the price does not poor, but compared with thus saving medical expenses and treatment time, or it's a good deal. 

 

According to the American association of pharmaceutical industry experts, to drug (trade name cubicin) since the first listed in the U.S. in 2004, quickly by the country's clinical doctors used against infectious diseases caused by different kinds of resistant strains of main drugs. It jumped in the sales in the United States, 2005, 2006, 2007, 2008, respectively, for $100 million, $198.5 million, $285.1 million and $285.1 million, 2016, at an astonishing $975.3 million. 

 

European and American market for the ideal 

 

Because of the medical market is still a lack of effective against resistant strains caused by infectious disease of the drug, and supporting to fill the market blank, it become one of the best antibacterial drugs in the United States market. And public history of more than 30 years of semi-synthetic penicillin and cephalosporin were retired in the American market. 

 

Still in the American pharmaceutical association figures mingda genetically altered the importance of clinical medicine in the country. By 2014, according to the foreign medical media of Joe toxin has dominated a 83% share of the American antibiotics for injection products. Nearly according to western media reports, in 2016 the world's 10 best-selling antibiotics only (antibacterial) product sales charts, cubicin (drug) were in eighth position and defeated the former of cephalosporins and semisynthetic penicillin + (the above list only AUGMENTIN amoxicillin clavulanic acid potassium mixture on the list). 

 

Comprehensive foreign medical media messages, last year's global reach total sales of approximately $1.6 billion to $1.7 billion, among them, the U.S. market for supporting drug sales accounted for about 58% of the world's total sales. According to foreign reports, India has become after eli lilly, of genetically altered the largest country in the production. Because India does not have to participate in the international patent organization, can free generic API products from foreign pharmaceutical companies, but subject to reach Joe is still in the patent protection period, self-marketing, only can't export of fosomycin API products. 

 

Due to Joe doxycycline injection is expensive, the drug has just 10 years ago to enter our country sales at the retail price is as high as 2000 yuan, per reason of doxycycline although has been listed on the global more than 50 countries and regions, but in the other country except the United States and Europe (region) market is not ideal. 

 

Goods listed 

 

A few years ago, the pharmaceutical enterprises in our country has begun in laboratory of generic drug small kind and successful. , zhejiang sea are pharmaceutical group and hangzhou sino-us east China pharmaceutical company has respectively in 2015 won the state food and drug supervision and management of the administration of fosomycin API production approval, then two pharmaceutical companies, namely jiangsu hengrui company and jiangsu sdsensor pharmaceutical companies, have given up to take drug API production approval. 

 

But it is understood that the sea is pharmaceutical group in the fastest progress on the preparation of drug production line, the group has built a year ago of 5 tons of doxycycline API production line. Relevant departments of the expectations, the group will be the latest within 2 years production of fosomycin API and injection products. Berbatov hangzhou sino-us east China pharmaceutical companies for drug production line there is no exact production news. As for the two companies in jiangsu of toxin production line may be in the planning stages. 

 

To sum up, once the conquer of toxin production technology, the product will be expected to become the growth of the domestic antibiotic industry new luminescent spot. Because in the international market, for drug varieties of antibiotics has been regarded as the most growth potential, but its high retail price limit its rapid growth in the international market. 

 

Once our pharmaceutical enterprises can mass production this kind of disease can be effective against resistant strains of antibiotic drugs, believe that the domestic of tora toxin listed will be able to significantly reduce their retail price, make the third world countries people can afford this kind of new antibiotics.